Q1 Earnings Estimate for Septerna Issued By HC Wainwright

Septerna, Inc. (NASDAQ:SEPN) – Analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Septerna in a research report issued to clients and investors on Wednesday, March 11th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.75) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.81) EPS and Q4 2027 earnings at ($0.88) EPS.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Septerna had a negative return on equity of 15.85% and a negative net margin of 106.37%.The business had revenue of $24.12 million during the quarter, compared to analyst estimates of $20.44 million.

SEPN has been the topic of several other reports. Raymond James Financial initiated coverage on shares of Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective on the stock. Wells Fargo & Company raised their price target on shares of Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, January 22nd. Truist Financial lifted their price target on Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Septerna Stock Performance

Septerna stock opened at $26.31 on Thursday. The stock has a market capitalization of $1.18 billion, a P/E ratio of -23.70 and a beta of 3.46. The company’s fifty day moving average price is $26.86 and its 200 day moving average price is $23.27. Septerna has a 1 year low of $4.66 and a 1 year high of $32.63.

Institutional Trading of Septerna

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of Septerna during the 4th quarter worth $88,000. Seven Fleet Capital Management LP acquired a new position in shares of Septerna during the 4th quarter valued at about $319,000. XTX Topco Ltd purchased a new stake in shares of Septerna in the fourth quarter valued at about $650,000. VARCOV Co. acquired a new stake in Septerna during the fourth quarter worth about $631,000. Finally, Virtus Investment Advisers LLC acquired a new stake in Septerna during the fourth quarter worth about $292,000.

Insider Buying and Selling

In related news, insider Samira Shaikhly sold 70,453 shares of Septerna stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the transaction, the insider owned 793 shares in the company, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at $5,046,834.73. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.30% of the stock is owned by corporate insiders.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.